REG-Syncona Limited: Change in Investment Manager <Origin Href="QuoteRef">SYNCS.L</Origin>

SynconaAnnouncement

12/12/2017 15:25

Syncona Limited

Change in Investment Manager

12 December 2017

Syncona Ltd, a leading healthcare company focused on investing in and building
global leaders in life science, today announces that it has appointed its
subsidiary Syncona Investment Management Limited (SIML) as its investment
manager and AIFM for the purposes of the AIFM Directive.  This appointment is
with effect from 12 December 2017 and is as envisaged at the time of the
change of the Company’s investment policy and acquisition of the life
science portfolio of Syncona Partners LLP approved by the Company’s
shareholders in December 2016.

BACIT (UK) Limited, the former investment manager and AIFM of the Company,
continues to be engaged by SIML as a sub-delegate to manage the funds
portfolio, on the same terms.

 ENDS 

Enquiries

Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031

 

Notes to Editors

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of
healthcare while generating superior returns for shareholders. Our current
investment portfolio consists of seven high quality companies in life science
and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in
science to build globally competitive businesses. We are established leaders
in gene therapy, cell therapy and advanced diagnostics, and focus on
delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and
succeed.

Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business.  We make a donation of
0.3% of Net Asset Value to a range of charities each year.



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved